<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2cd0fab6-ef19-4c4d-9cb3-97991174b178"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TEVIMBRA safely and effectively. See full prescribing information for TEVIMBRA. <br/>
      <br/> TEVIMBRA<sup>®</sup> (tislelizumab-jsgr) injection, for intravenous use <br/> Initial U.S. Approval: 2024</title>
   <effectiveTime value="20250306"/>
   <setId root="08ef1e3e-496f-4b0b-94ee-fbba3cc1985a"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="081210042" root="1.3.6.1.4.1.519.1"/>
            <name>BEIGENE USA, INC.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="544325726" root="1.3.6.1.4.1.519.1"/>
                        <name>Boehringer Ingelheim Biopharmaceuticals (China) Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="543941083" root="1.3.6.1.4.1.519.1"/>
                        <name>Beigene (Suzhou) Co.,Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="117503828" root="1.3.6.1.4.1.519.1"/>
                        <name>Sharp Packaging Services, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="343903364" root="1.3.6.1.4.1.519.1"/>
                        <name>Microcoat Biotechnologie GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="2ef19e36-6ad9-4b82-ab59-caa9914130da"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250306"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72579-121" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TEVIMBRA</name>
                        <formCode code="C42899" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION, CONCENTRATE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>tislelizumab-jsgr</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0KVO411B3N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TISLELIZUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0KVO411B3N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TISLELIZUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.42" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="2.54" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.2" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7T1F30V5YH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="5.93" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="65.04" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B8WCK70T7I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72579-121-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240314"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761232" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240314"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="3d84a368-0e1f-405f-9c38-89bad222b78a"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="80%" align="left" valign="top"/>
                           <col width="20%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1.1">1.1</linkHtml>, <linkHtml href="#S1.2">1.2</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="d26c79f9-c6ca-4d3d-b833-36999bbd087e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for:</paragraph>
                        <paragraph>Esophageal Cancer</paragraph>
                        <list listType="unordered">
                           <item>in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                        </list>
                        <paragraph>Gastric Cancer</paragraph>
                        <list listType="unordered">
                           <item>in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="5494b908-f4ec-4a66-9a6b-50bfa19e3f45"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Esophageal Cancer </title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>First-Line Treatment of Esophageal Squamous Cell Carcinoma </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).</content>
                        </paragraph>
                        <list>
                           <item>Previously Treated Esophageal Squamous Cell Carcinoma</item>
                        </list>
                        <paragraph>TEVIMBRA, as a single agent, is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="2a62b4b6-ddf8-437c-b88d-4fbd5eb014fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Gastric Cancer </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) whose tumors express PD-L1 (≥1).</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="09c6335f-c8d7-4cef-baf3-9ed60d04bade"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Recommended Dosage: 200 mg as an intravenous infusion every 3 weeks. Administer the first infusion over 60 minutes. If tolerated, subsequent infusions may be administered over 30 minutes. (<linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="1735dd74-2d9c-4976-af01-6b987ec8948a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Patient Selection </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Select patients for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma based on the presence of PD-L1 in tumor specimens <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content> An FDA-approved companion diagnostic for the detection of PD-L1 in patients with unresectable or metastatic esophageal squamous cell carcinoma is not available.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Select patients for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) based on the presence of PD-L1 in tumor specimens <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. An FDA-approved companion diagnostic for the detection of PD-L1 in patients with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) is not available.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="a3d9efcd-2e23-4c5f-b047-8c487d249e40"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The recommended dosage of TEVIMBRA as a single agent or in combination with chemotherapy is 200 mg administered as an intravenous infusion every 3 weeks until disease progression or unacceptable toxicity <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1</linkHtml>, <linkHtml href="#S14.2">14.2)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Refer to the respective Prescribing Information for each therapeutic agent administered in combination with TEVIMBRA for the recommended dosage information, as appropriate.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="bcb2c3cf-4186-455d-8704-5bd762959964"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Modifications for Adverse Reactions </title>
                     <text>
                        <paragraph>No dose reduction of TEVIMBRA is recommended. In general, withhold TEVIMBRA for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue TEVIMBRA for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone equivalent per day within 12 weeks of initiating steroids <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Dosage modifications for TEVIMBRA for adverse reactions that require management different from these general guidelines are summarized in Table 1<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Refer to the respective Prescribing Information for dosage modifications for the platinum and fluoropyrimidine agent administered in combination with TEVIMBRA.</paragraph>
                        <table width="85%">
                           <caption>Table 1:	Recommended Dosage Modifications for Adverse Reactions</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="left" valign="top"/>
                           <col width="33%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                 <th styleCode="Rrule">Severity of Adverse Reaction<footnote>Based on Common Terminology Criteria for Adverse Events (CTCAE) Version 4.</footnote>
                                 </th>
                                 <th styleCode="Rrule">Dosage Modifications</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis, DRESS = drug rash with eosinophilia and systemic symptoms.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Immune-Mediated Adverse Reactions </content>
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Pneumonitis</td>
                                 <td styleCode="Rrule">Grade 2</td>
                                 <td styleCode="Rrule">Withhold<footnote ID="Tb1ftb">Resume in patients with complete or partial resolution (Grades 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids.</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Grade 3 or 4 or recurrent Grade 2 </td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Colitis</td>
                                 <td styleCode="Rrule">Grade 2 or 3 </td>
                                 <td styleCode="Rrule">Withhold<footnoteRef IDREF="Tb1ftb"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Grade 4</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Hepatitis with no tumor involvement of the liver</td>
                                 <td styleCode="Rrule">AST or ALT increases to more than 3 and up to 8 times ULN<br/>or<br/>Total bilirubin increases to more than 1.5 and up to 3 times ULN</td>
                                 <td styleCode="Rrule">Withhold<footnoteRef IDREF="Tb1ftb"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">AST or ALT increases to more than 8 times ULN<br/>or<br/>Total bilirubin increases to more than 3 times ULN</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Hepatitis with tumor involvement of the liver<footnote>If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue TEVIMBRA based on recommendations for hepatitis with no liver involvement.</footnote>
                                 </td>
                                 <td styleCode="Rrule">Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN<br/>or<br/>Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN</td>
                                 <td styleCode="Rrule">Withhold<footnoteRef IDREF="Tb1ftb"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">ALT or AST increases to more than 10 times ULN<br/>or<br/>Total bilirubin increases to more than 3 times ULN</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Endocrinopathies</td>
                                 <td styleCode="Rrule">Grade 3 or 4</td>
                                 <td styleCode="Rrule">Withhold until clinically stable or permanently discontinue depending on severity</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Nephritis with renal dysfunction</td>
                                 <td styleCode="Rrule">Grade 2 or 3 increased blood creatinine</td>
                                 <td styleCode="Rrule">Withhold<footnoteRef IDREF="Tb1ftb"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Grade 4 increased blood creatinine</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule">Exfoliative dermatologic conditions</td>
                                 <td styleCode="Rrule">Grade 3, or suspected SJS, TEN, or DRESS</td>
                                 <td styleCode="Rrule">Withhold<footnoteRef IDREF="Tb1ftb"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Grade 4, or confirmed SJS, TEN, or DRESS</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Myocarditis</td>
                                 <td styleCode="Rrule">Grade 2, 3, or 4</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">Neurological toxicities</td>
                                 <td styleCode="Rrule">Grade 2</td>
                                 <td styleCode="Rrule">Withhold<footnoteRef IDREF="Tb1ftb"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule">Grade 3 or 4</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Other Adverse Reactions</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Rrule">Infusion-related reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Botrule Rrule">Grade 1 </td>
                                 <td styleCode="Botrule Rrule">Slow infusion rate by 50%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Botrule Lrule Rrule">Grade 2</td>
                                 <td styleCode="Botrule Rrule">Interrupt infusion<footnote>Resume infusion if resolved or decreased to Grade 1, and slow rate of infusion by 50% of the previous rate.</footnote>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">Grade 3 or 4</td>
                                 <td styleCode="Rrule">Permanently discontinue</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="185c9d06-24a3-4801-b32b-b2a3bbd8c5de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Preparation and Administration </title>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="4976a1af-d2cb-4c52-9858-b9a7f600f862"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation</content>
                              </paragraph>
                              <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. TEVIMBRA is a clear to slightly opalescent, colorless to slightly yellow solution. Discard the vial if the solution is cloudy, discolored, or contains visible particles. Do not shake the vial.</paragraph>
                              <paragraph>Prepare the solution for infusion as follows:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Withdraw 20 mL of TEVIMBRA from two vials of TEVIMBRA (for a total of 200 mg in 20 mL).</item>
                                 <item>Transfer solution into an intravenous infusion bag containing 0.9% Sodium Chloride Injection, USP to prepare an infusion solution with a final concentration of 2 mg/mL to 5 mg/mL.</item>
                                 <item>Mix diluted solution by gentle inversion to avoid foaming or excessive shearing of the solution. Do not shake.</item>
                                 <item>TEVIMBRA is for single use only. Discard any unused portion left in the vial.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="903afa4b-eeec-4f1f-9b9c-12a9b39be948"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Storage of Diluted Solution</content>
                              </paragraph>
                              <paragraph>This product does not contain any preservatives. If not used immediately, store the TEVIMBRA diluted solution either:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>At room temperature at 20°C to 25°C (68°F to 77°F) for up to 4 hours, including preparation and infusion duration. Discard after 4 hours.</item>
                                 <item>Under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 20 hours, including preparation and infusion duration. Allow the diluted solution to come to room temperature prior to administration. Discard after 20 hours.</item>
                              </list>
                              <paragraph>Do not freeze the diluted solution.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ed156c4d-afd0-45e0-b8e3-28e00ef78e86"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Administer diluted solution by intravenous infusion through an intravenous line with a sterile, nonpyrogenic, low protein binding 0.2 micron or 0.22 micron in-line or add-on filter.</item>
                                 <item>The initial infusion should be delivered over 60 minutes. If tolerated, all subsequent infusions may be administered over 30 minutes.</item>
                                 <item>Do NOT coadminister other drugs through the same infusion line.</item>
                                 <item>Do NOT administer TEVIMBRA as an intravenous push or single bolus injection.</item>
                                 <item>Flush the intravenous line at the end of infusion.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="5fe55562-02e0-414e-83fd-90fba3fabca1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 100 mg/10 mL (10 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="1e657210-d8ee-4d0f-8332-feaf47889da4"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="2127cc06-2113-4a31-8acc-1601aa075e40"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Immune-Mediated Adverse Reactions</content>: (<linkHtml href="#S5.1">5.1</linkHtml>) 									<list listType="unordered" styleCode="circle">
                                 <item>Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection.</item>
                                 <item>Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.</item>
                                 <item>Withhold or permanently discontinue TEVIMBRA based on the severity of reaction.</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Infusion-Related Reactions</content>: Slow the rate of infusion, interrupt, or permanently discontinue based on severity of infusion reaction. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</content>: Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="067278b3-3b71-4264-8d0e-4e93f9ab4104"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Severe and Fatal Immune-Mediated Adverse Reactions </title>
                     <text>
                        <paragraph>TEVIMBRA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under WARNINGS AND PRECAUTIONS may not include all possible severe and fatal immune-mediated reactions.</paragraph>
                        <paragraph>Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.</paragraph>
                        <paragraph>Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</paragraph>
                        <paragraph>Withhold or permanently discontinue TEVIMBRA depending on severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>. In general, if TEVIMBRA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroids.</paragraph>
                        <paragraph>Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="3d82e635-67a9-41a2-802f-7d209982dc24"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immune-Mediated Pneumonitis</content>
                              </paragraph>
                              <paragraph>TEVIMBRA can cause immune-mediated pneumonitis, which can be fatal. In patients treated with other PD-1/PD-L1 blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation.</paragraph>
                              <paragraph>Immune-mediated pneumonitis occurred in 4.9% (96/1972) of patients receiving TEVIMBRA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (1.6%), and Grade 2 (1.9%) adverse reactions. Pneumonitis led to permanent discontinuation of TEVIMBRA in 38 (1.9%) patients and withholding of TEVIMBRA in 32 (1.6%) patients.</paragraph>
                              <paragraph>Seventy-four (77.1%) of the 96 patients received systemic corticosteroids. Sixty-five (67.7%) of the 96 patients received high-dose systemic corticosteroids. Immune-mediated pneumonitis resolved in 50% of the 96 patients. Of the 32 patients in whom TEVIMBRA was withheld for pneumonitis, 20 (62.5%) reinitiated TEVIMBRA after symptom improvement; of these, 2 (10%) patients had recurrence of pneumonitis.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0750d7ea-2140-4468-9961-eb154ec66b51"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immune-Mediated Colitis</content>
                              </paragraph>
                              <paragraph>TEVIMBRA can cause immune-mediated colitis, which can be fatal. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1 blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.</paragraph>
                              <paragraph>Immune-mediated colitis occurred in 0.8% (16/1972) of patients receiving TEVIMBRA, including Grade 3 (0.3%) and Grade 2 (0.4%) adverse reactions. Colitis led to permanent discontinuation of TEVIMBRA in 4 (0.2%) patients and withholding of TEVIMBRA in 5 (0.3%) patients. Twelve (75%) of the 16 patients received systemic corticosteroids. Eight (50%) of the 16 patients received high-dose systemic corticosteroids. Two (12.5%) of the 16 patients received immunosuppressive treatment. Immune-mediated colitis resolved in 93.8% of the 16 patients. All 5 patients in whom TEVIMBRA was withheld for colitis reinitiated TEVIMBRA after symptom improvement; of these, none of the patients had recurrence of colitis.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="25b4d59c-11c6-4cfd-82b3-cbf1787b3e6c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immune-Mediated Hepatitis</content>
                              </paragraph>
                              <paragraph>TEVIMBRA can cause immune-mediated hepatitis, which can be fatal.</paragraph>
                              <paragraph>Immune-mediated hepatitis occurred in 1.2% (24/1972) of patients receiving TEVIMBRA, including fatal (0.1%), Grade 4 (0.2%), Grade 3 (0.5%), and Grade 2 (0.4%) adverse reactions. Immune-mediated hepatitis led to permanent discontinuation in 3 (0.2%) patients and withholding of TEVIMBRA in 13 (0.7%) patients. Eighteen (75%) of the 24 patients received systemic corticosteroids. Thirteen (54.2%) of the 24 patients received high-dose systemic corticosteroids. Two (8.3%) of the 24 patients received immunosuppressive treatment. Immune-mediated hepatitis resolved in 70.8% of the 24 patients. Of the 13 patients in whom TEVIMBRA was withheld for hepatitis, 7 (53.8%) reinitiated TEVIMBRA after symptom improvement; of these, none of the patients had recurrence of hepatitis.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1b249747-f11b-45f1-8405-2f3f179d4326"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immune-Mediated Endocrinopathies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                           <component>
                              <section>
                                 <id root="69a95254-8b77-4697-ba3f-d988fb7e1c6d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Adrenal Insufficiency</content>
                                    </paragraph>
                                    <paragraph>TEVIMBRA can cause immune-mediated adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold TEVIMBRA depending on severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                                    <paragraph>Immune-mediated adrenal insufficiency occurred in 0.4% (8/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1%), Grade 3 (0.1%), and Grade 2 (0.3%) adverse reactions. Adrenal insufficiency did not lead to permanent discontinuation of TEVIMBRA. TEVIMBRA was withheld in 7 out of 8 patients. All 8 patients received systemic corticosteroids. Three (37.5%) of the 8 patients received high-dose systemic corticosteroids. Adrenal insufficiency resolved in 25% of the 8 patients. Of the 7 patients in whom TEVIMBRA was withheld for adrenal insufficiency, 5 (71.4%) reinitiated TEVIMBRA after symptom improvement; of these, none of the patients had recurrence of adrenal insufficiency.</paragraph>
                                 </text>
                                 <effectiveTime value="20250306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="509b9a4b-2cbe-4179-860f-ad6082747bf3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hypophysitis</content>
                                    </paragraph>
                                    <paragraph>TEVIMBRA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue TEVIMBRA depending on severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                                    <paragraph>Hypophysitis/hypopituitarism occurred in 0.2% (4/1972) of patients receiving TEVIMBRA, including Grade 2 (0.2%) adverse reactions. Hypophysitis did not lead to permanent discontinuation in any patient, while treatment was withheld in 1 (0.1%) patient. Three (75%) of the 4 patients received systemic corticosteroids. One (25%) of the 4 patients received high-dose systemic corticosteroids. Hypophysitis/hypopituitarism did not resolve in the 4 patients. For the 1 patient where TEVIMBRA was withheld for hypophysitis/hypopituitarism, there was no recurrence of hypophysitis/hypopituitarism.</paragraph>
                                 </text>
                                 <effectiveTime value="20250306"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0d54b0df-e37d-4d62-860a-effe50ce7628"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Thyroid Disorders</content>
                                    </paragraph>
                                    <paragraph>TEVIMBRA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue TEVIMBRA depending on severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250306"/>
                                 <component>
                                    <section>
                                       <id root="eed644c8-851f-48ae-a71c-3a46378f680a"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Thyroiditis:</content> Immune-mediated thyroiditis occurred in 1.2% (24/1972) of patients receiving TEVIMBRA, including Grade 2 (0.5%) adverse reactions. Thyroiditis did not lead to permanent discontinuation of TEVIMBRA. TEVIMBRA was withheld in 3 (0.2%) patients. Two (8.3%) of the 24 patients received systemic corticosteroids. Thyroiditis resolved in 41.7% of the 24 patients. All three patients in whom TEVIMBRA was withheld for thyroiditis reinitiated TEVIMBRA after symptom improvement; of these, none of the patients had recurrence of thyroiditis.</paragraph>
                                       </text>
                                       <effectiveTime value="20250306"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="e6732182-b959-40bc-8e03-857abbb505be"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Hyperthyroidism:</content> Immune-mediated hyperthyroidism occurred in 4.8% (95/1972) of patients receiving TEVIMBRA, including Grade 3 (0.1%) and Grade 2 (0.9%) adverse reactions. Hyperthyroidism led to the permanent discontinuation of TEVIMBRA in 1 (0.1%) patient and withholding of TEVIMBRA in 4 (0.2%) patients. One (1.1%) of the 95 patients received systemic corticosteroids. Hyperthyroidism resolved in 75.8% of the 95 patients. Of the 4 patients in whom TEVIMBRA was withheld for hyperthyroidism, 3 (75%) reinitiated TEVIMBRA after symptom improvement; of these, none of the patients had recurrence of hyperthyroidism.</paragraph>
                                       </text>
                                       <effectiveTime value="20250306"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="f52b1043-5d30-4590-961a-66b17ea16c7f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Hypothyroidism:</content> Immune-mediated hypothyroidism occurred in 12.7% (250/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1%) and Grade 2 (6.8%) adverse reactions. TEVIMBRA was not permanently discontinued in any patient, while treatment was withheld in 7 (0.4%) patients. Two (0.8%) of the 250 patients received systemic corticosteroids. One hundred fifty-eight patients (63.2%) received hormone replacement therapy. Hypothyroidism resolved in 31.6% of the 250 patients. The majority (54%) of patients with hypothyroidism required long-term thyroid hormone replacement. Of the 7 patients in whom TEVIMBRA was withheld for hypothyroidism, 6 (85.7%) reinitiated TEVIMBRA after symptom improvement; of these, none of the patients had recurrence of hypothyroidism.</paragraph>
                                       </text>
                                       <effectiveTime value="20250306"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="cf7aa711-cb16-4756-bdc0-3e2383c759ed"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis</content>
                                    </paragraph>
                                    <paragraph>Diabetes mellitus has been reported with PD-1/PD-L1 blocking antibodies. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue TEVIMBRA depending on severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                                    <paragraph>Diabetes mellitus occurred in 0.9% (18/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1%), Grade 3 (0.4%), and Grade 2 (0.4%) adverse reactions. TEVIMBRA was permanently discontinued in 3 (0.2%) patients and TEVIMBRA treatment was withheld in 3 (0.2%) patients. Twelve (66.7%) patients received insulin therapy for diabetes mellitus. Diabetes mellitus resolved in 27.8% of the 18 patients. Of the 3 patients in whom TEVIMBRA was withheld for diabetes mellitus, none of the patients reinitiated TEVIMBRA after symptom improvement. </paragraph>
                                 </text>
                                 <effectiveTime value="20250306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9d0aa47e-34b7-4f6d-9192-e9ca1809077d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immune-Mediated Nephritis with Renal Dysfunction</content>
                              </paragraph>
                              <paragraph>TEVIMBRA can cause immune-mediated nephritis, which can be fatal.</paragraph>
                              <paragraph>Immune-mediated nephritis with renal dysfunction occurred in 0.3% (6/1972) of patients receiving TEVIMBRA, including Grade 3 (0.1%) and Grade 2 (0.2%) adverse reactions. TEVIMBRA was permanently discontinued in 1 (0.1%) patient and treatment was withheld in 3 (0.2%) patients. Three (50%) patients received systemic corticosteroids. Three (50%) of the 6 patients received high-dose systemic corticosteroids. Nephritis with renal dysfunction resolved in 33.3% of the 6 patients. Of the 3 patients in whom TEVIMBRA was withheld for nephritis, 2 (66.7%) reinitiated TEVIMBRA after symptom improvement; of these, one (50%) patient had recurrence of nephritis.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8fe7c58d-b649-4f92-937f-5b44de87c4cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immune-Mediated Dermatologic Adverse Reactions</content>
                              </paragraph>
                              <paragraph>TEVIMBRA can cause immune-mediated rash or dermatitis. Cases of severe cutaneous adverse reactions (SCARs), including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), have been reported, some with fatal outcomes. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue TEVIMBRA depending on severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>Immune-mediated dermatologic adverse reactions occurred in 15.3% (301/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1%), Grade 3 (0.9%), and Grade 2 (3.5%) adverse reactions. Dermatologic adverse reactions led to permanent discontinuation of TEVIMBRA in 2 (0.1%) patients and withholding of TEVIMBRA in 18 (0.9%) patients, thirty (10%) of the 301 patients received systemic corticosteroids. Thirteen (4.3%) of the 301 patients received high-dose systemic corticosteroids. Immune-mediated dermatologic adverse reactions resolved in 63.1% of the 301 patients. Of the 18 patients in whom TEVIMBRA was withheld for dermatologic adverse reactions, 15 (83.3%) reinitiated TEVIMBRA after symptom improvement; of these, 1 (6.7%) patient had recurrence of immune-mediated dermatologic adverse reaction.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="65eb9a64-1994-4361-ad01-1230f689e1e0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Immune-Mediated Adverse Reactions</content>
                              </paragraph>
                              <paragraph>The following clinically significant immune-mediated adverse reactions occurred at an incidence of less than 1% each in patients who received TEVIMBRA: myositis, myocarditis, arthritis, polymyalgia rheumatica, encephalitis, myasthenia gravis, Sjogren's syndrome, and pericarditis. </paragraph>
                              <paragraph>The following additional clinically significant immune-mediated adverse reactions have been reported with other PD-1/PD-L1 blocking antibodies, including severe or fatal cases.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Cardiac/Vascular:</content> Vasculitis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Nervous System: </content>Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Ocular:</content> Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal:</content> Pancreatitis including increases in serum amylase and lipase levels, gastritis, duodenitis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Musculoskeletal and Connective Tissue:</content> Polymyositis, rhabdomyolysis and associated sequelae including renal failure.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Endocrine:</content> Hypoparathyroidism.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Other (Hematologic/Immune):</content> Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="f2eb08f3-7c02-4804-8380-378b9305cc99"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Infusion-Related Reactions </title>
                     <text>
                        <paragraph>TEVIMBRA can cause severe or life-threatening infusion-related reactions. Infusion-related reactions occurred in 5% (99/1972) patients receiving TEVIMBRA, including Grade 3 or higher (0.2%) reactions. Monitor patients for signs and symptoms of infusion-related reactions.</paragraph>
                        <paragraph>Slow the rate of infusion for mild (Grade 1) and interrupt the infusion for moderate (Grade 2) infusion-related reactions. For severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue TEVIMBRA <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="f359b3ed-caa5-4d33-a718-2e2c1e41d4cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Complications of Allogeneic HSCT</title>
                     <text>
                        <paragraph>Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT.</paragraph>
                        <paragraph>Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="e65310c2-0d1f-4cf2-a0be-a37d8eecfb75"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Embryo-Fetal Toxicity </title>
                     <text>
                        <paragraph>Based on its mechanism of action, TEVIMBRA can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TEVIMBRA and for 4 months after the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="a35fd0fa-ac5c-4d3e-be39-ed898382ea39"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in more detail in other sections of the label:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Severe and fatal immune-mediated adverse reactions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Infusion-related reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (≥20%), including laboratory abnormalities, were:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>TEVIMBRA in combination with platinum-containing chemotherapy: decreased neutrophil count, decreased sodium, increased glucose, anemia, fatigue, decreased appetite, increased AST, decreased potassium, increased serum creatinine, decreased calcium, increased ALT, diarrhea, stomatitis, and vomiting. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>TEVIMBRA as a single agent: increased glucose, decreased hemoglobin, decreased lymphocytes, decreased sodium, decreased albumin, increased alkaline phosphatase, anemia, fatigue, increased AST, musculoskeletal pain, decreased weight, increased ALT, and cough. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy: nausea, fatigue, decreased appetite, anemia, peripheral sensory neuropathy, vomiting, decreased platelet count, decreased neutrophil count, increased aspartate aminotransferase, diarrhea, abdominal pain, increased alanine aminotransferase, decreased white blood cell count, decreased weight, and pyrexia. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact BeiGene at 1-877-828-5596 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="5e4244c1-1a08-402c-b1e8-5be4ff245947"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety population described in WARNINGS AND PRECAUTIONS reflect exposure to TEVIMBRA as a single agent in 1972 patients enrolled in two randomized open-label, active-controlled studies (RATIONALE-302, BGB-A317-303) and five open-label, single-arm studies (BGB-A317-208, BGB-A317-204, BGB-A317-203, BGB-A317-102, BGB-A317_Study_001), which enrolled 307 patients with esophageal squamous cell carcinoma and 1665 patients with advanced or recurrent tumors. TEVIMBRA was administered at a dose of 200 mg intravenously once every 3 weeks, except in study BGB-A317_Study_001 where patients also received other dosage regimens. Among the 1972 patients, 37.8% were exposed for longer than 6 months, and 21.8% were exposed for longer than 12 months.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="27f6d303-e1dc-4f6e-9fc8-ed4db24c296a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">First-line Treatment of Unresectable or Metastatic Esophageal Carcinoma (ESCC)</content>
                              </paragraph>
                              <paragraph>The safety of TEVIMBRA in combination with chemotherapy was evaluated in RATIONALE-306, a randomized, placebo-controlled, multicenter, double-blind trial in patients with unresectable, advanced, or metastatic ESCC <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>.</paragraph>
                              <paragraph>Patients were randomized (1:1) to receive either TEVIMBRA 200 mg by intravenous infusion over 30-60 minutes every 3 weeks or placebo plus a chemotherapy doublet regimen. The chemotherapy doublet regimens consisted of:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Platinum (cisplatin [60 to 80 mg/m<sup>2</sup> IV, on Day 1] or oxaliplatin [130 mg/m<sup>2</sup> IV, on Day 1]) and a fluoropyrimidine (5-FU [750 to 800 mg/m<sup>2</sup> IV, on Day 1 to 5] or capecitabine [1000 mg/m<sup>2</sup> orally twice daily, on Day 1 to 14]),</item>
                              </list>
                              <paragraph>or</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Platinum (cisplatin [60 to 80 mg/m<sup>2</sup> IV, on Day 1 or 2] or oxaliplatin [130 mg/m<sup>2</sup> IV, on Day 1 or 2]) and (paclitaxel 175 mg/m<sup>2</sup> IV, on Day 1)</item>
                              </list>
                              <paragraph>Patients were treated until disease progression or unacceptable toxicity. The median duration of exposure was 6.4 months (range: 0.1 to 38.3 months) in TEVIMBRA-treated patients.</paragraph>
                              <paragraph>Serious adverse reactions occurred in 48% of patients receiving TEVIMBRA in combination with chemotherapy. The most frequent serious adverse reactions (≥2%) were pneumonia (5.2%), dysphagia (5.2%), diarrhea (2.2%), fatigue (2.2%), and esophageal stenosis (2.2%). Fatal adverse reactions occurred in 8% of patients who received TEVIMBRA in combination with chemotherapy.</paragraph>
                              <paragraph>Permanent discontinuation of TEVIMBRA due to adverse reactions occurred in 13% of patients. The adverse reaction which resulted in discontinuation in ≥2% of patients was pneumonitis (2.2%).</paragraph>
                              <paragraph>Dosage interruptions of TEVIMBRA due to adverse reactions occurred in 52% of patients. Adverse reactions which required dosage interruption in ≥2% of patients were neutrophil count decreased (7%), fatigue (6%), pneumonia (6%), anemia (4.3%), neutropenia (4.3%), white blood cell count decreased (4.3%), rash (3.7%), dysphagia (2.8%), platelet count decreased (2.8%), pyrexia (2.8%), and diarrhea (2.2%).</paragraph>
                              <paragraph>The most common (≥20%) adverse reactions including laboratory abnormalities were decreased neutrophil count, decreased sodium, increased glucose, anemia, fatigue, decreased appetite, increased AST, decreased potassium, increased serum creatinine, decreased calcium, increased ALT, diarrhea, stomatitis, and vomiting.</paragraph>
                              <paragraph>Adverse reactions and laboratory abnormalities are listed in Table 2 and Table 3, respectively.</paragraph>
                              <table width="80%">
                                 <caption>Table 2: Adverse Reactions (≥10%) in Patients with ESCC Receiving TEVIMBRA + Chemotherapy with a Difference Between Arms of ≥5% for All Grades or ≥2% for Grades 3 and 4 vs Placebo + Chemotherapy in RATIONALE-306</caption>
                                 <col width="32%" align="left" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Adverse Reaction</th>
                                       <th styleCode="Rrule" colspan="2">TEVIMBRA + Chemotherapy <br/>N=324</th>
                                       <th styleCode="Rrule" colspan="2">Placebo + Chemotherapy <br/>N=321</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">All Grades<br/> %</th>
                                       <th styleCode="Rrule">Grades 3 or 4<br/> %</th>
                                       <th styleCode="Rrule">All Grades<br/> %</th>
                                       <th styleCode="Rrule">Grades 3 or 4<br/> %</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Blood and Lymphatic System Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anemia</td>
                                       <td styleCode="Rrule">61</td>
                                       <td styleCode="Rrule">17</td>
                                       <td styleCode="Rrule">56</td>
                                       <td styleCode="Rrule">16</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Neutropenia</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">10</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue<footnote ID="t2ft1">Represents a composite of multiple, related preferred terms.</footnote>
                                       </td>
                                       <td styleCode="Rrule">45</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">45</td>
                                       <td styleCode="Rrule">4.7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased Appetite</td>
                                       <td styleCode="Rrule">44</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">39</td>
                                       <td styleCode="Rrule">2.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">28</td>
                                       <td styleCode="Rrule">4.3</td>
                                       <td styleCode="Rrule">24</td>
                                       <td styleCode="Rrule">1.9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Stomatitis<footnoteRef IDREF="t2ft1"/>
                                       </td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">2.2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">2.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dysphagia</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash<footnoteRef IDREF="t2ft1"/>
                                       </td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">0.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">0.3</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Endocrine Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypothyroidism<footnoteRef IDREF="t2ft1"/>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="80%">
                                 <caption>Table 3:	 Select Laboratory Abnormalities Worsening From Baseline Occurring in ≥10% of Patients Receiving TEVIMBRA in Combination with Chemotherapy in RATIONALE-306 with a Difference Between Arms of ≥5% for All Grades or ≥2% for Grades 3 and 4 vs Placebo + Chemotherapy in RATIONALE-306</caption>
                                 <col width="32%" align="left" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Laboratory Abnormality</th>
                                       <th styleCode="Rrule" colspan="2">TEVIMBRA + Chemotherapy<footnote ID="t3ft1">The denominator used to calculate the rate varied from 132 to 323 based on the number of patients with a baseline value and at least one post-treatment value.</footnote>
                                          <br/>(N=324)</th>
                                       <th styleCode="Rrule" colspan="2">Placebo + Chemotherapy<footnoteRef IDREF="t3ft1"/>
                                          <br/>(N=321)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                       <th styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Neutrophils decreased</td>
                                       <td styleCode="Rrule">75</td>
                                       <td styleCode="Rrule">41</td>
                                       <td styleCode="Rrule">75</td>
                                       <td styleCode="Rrule">46</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sodium decreased</td>
                                       <td styleCode="Rrule">67</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">62</td>
                                       <td styleCode="Rrule">11</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Glucose increased</td>
                                       <td styleCode="Rrule">65</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">61</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AST increased</td>
                                       <td styleCode="Rrule">36</td>
                                       <td styleCode="Rrule">3.4</td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">1.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Potassium decreased</td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">29</td>
                                       <td styleCode="Rrule">2.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Creatinine increased</td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">1.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Calcium decreased</td>
                                       <td styleCode="Rrule">29</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">24</td>
                                       <td styleCode="Rrule">4.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ALT increased</td>
                                       <td styleCode="Rrule">28</td>
                                       <td styleCode="Rrule">3.1</td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">1.6</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7f475f73-6514-4490-97ae-8fb362d88a7f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Previously Treated Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)</content>
                              </paragraph>
                              <paragraph>The safety of TEVIMBRA was evaluated in RATIONALE-302, a randomized, active-controlled, open-label, multicenter study in 255 patients with unresectable advanced, recurrent or metastatic ESCC <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. The trial excluded patients who had brain or leptomeningeal metastases that were symptomatic or required treatment, active autoimmune disease, a medical condition requiring systemic corticosteroids or immunosuppressants, or apparent tumor invasion of organs adjacent to the esophageal site.</paragraph>
                              <paragraph>Patients received TEVIMBRA 200 mg by intravenous infusion over 30-60 minutes every 3 weeks or investigator's choice: paclitaxel 135-175 mg/m<sup>2</sup> every 3 weeks or 80-100 mg/m<sup>2</sup> weekly, docetaxel 75 mg/m<sup>2</sup> every 3 weeks, or irinotecan 125 mg/m<sup>2</sup> on Days 1 and 8 of every 3-week cycle<content styleCode="italics">.</content> Patients were treated until disease progression or unacceptable toxicity. The median duration of exposure was 2.8 months (range: 0.2 to 28.3 months) in TEVIMBRA-treated patients and 1.5 months (range: 0.2 to 19.2 months) in paclitaxel, docetaxel, or irinotecan-treated patients.</paragraph>
                              <paragraph>Serious adverse reactions occurred in 41% of patients; the most frequent serious adverse reactions (≥2%) were pneumonia, dysphagia, hemorrhage, pneumonitis (including pneumonitis and immune-mediated pneumonitis), and esophageal obstruction. Fatal adverse reactions occurred in 7% of patients who received TEVIMBRA, including the following which occurred in more than one patient: pneumonia/pneumonitis (5 patients), hemorrhage (3 patients), and death due to an unknown cause (3 patients).</paragraph>
                              <paragraph>Permanent discontinuation of TEVIMBRA due to an adverse reaction occurred in 19% of patients. Adverse reactions which resulted in permanent discontinuation in ≥1% of patients were hemorrhage, pneumonitis (including pneumonitis and immune-mediated pneumonitis), and pneumonia.</paragraph>
                              <paragraph>Dosage interruptions of TEVIMBRA due to an adverse reaction occurred in 23% of patients. Adverse reactions which required dosage interruptions in ≥2% of patients were pneumonia, pneumonitis, and fatigue.</paragraph>
                              <paragraph>The most common (≥20%) adverse reactions were anemia, fatigue, musculoskeletal pain, decreased weight, and cough.</paragraph>
                              <paragraph>Adverse reactions and laboratory abnormalities are listed in Table 4 and Table 5, respectively.</paragraph>
                              <table width="85%">
                                 <caption>Table 4:	Adverse Reactions (≥10%) in Patients With ESCC Receiving TEVIMBRA in RATIONALE-302</caption>
                                 <col width="30%" align="left" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th rowspan="2" valign="middle" styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th colspan="2" styleCode="Botrule Rrule">TEVIMBRA<br/>(N=255)</th>
                                       <th colspan="2" styleCode="Botrule Rrule">ICC<br/>(N=240)</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                       <th align="center" styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">ICC = investigator's choice of chemotherapy</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Blood Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Anemia</td>
                                       <td styleCode="Rrule">31</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">45</td>
                                       <td styleCode="Rrule">11</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">General Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Fatigue<footnote>Fatigue includes asthenia, fatigue, malaise.</footnote>
                                       </td>
                                       <td styleCode="Rrule">28</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">46</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Pyrexia</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Musculoskeletal pain<footnote>Musculoskeletal pain includes musculoskeletal pain, spinal pain, arthralgia, back pain, neck pain, musculoskeletal chest pain, myalgia, pain in extremity, non-cardiac chest pain, bone pain, arthritis.</footnote>
                                       </td>
                                       <td styleCode="Rrule">24</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Investigations</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Weight decreased</td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Cough<footnote>Cough includes productive cough, cough.</footnote>
                                       </td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">0.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Decreased appetite</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">35</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Infections and Infestations</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Pneumonia<footnote>Pneumonia includes pneumonia aspiration, pneumonia, pneumonia bacterial, lower respiratory tract infection.</footnote>
                                       </td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Constipation</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">19</td>
                                       <td styleCode="Rrule">0.4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Nausea</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">30</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Diarrhea<footnote>Diarrhea includes diarrhea, colitis.</footnote>
                                       </td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">32</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Dysphagia</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Abdominal pain<footnote>Abdominal pain includes abdominal pain upper, abdominal pain, abdominal discomfort, abdominal pain lower, gastrointestinal pain.</footnote>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Vomiting</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Endocrine Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Hypothyroidism<footnote>Hypothyroidism includes hypothyroidism, blood thyroid stimulating hormone increased.</footnote>
                                       </td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Rash<footnote>Rash includes dermatitis, dermatitis acneiform, dermatitis allergic, eczema, erythema, psoriasis, rash, rash follicular, rash maculo-papular, rash pruritic.</footnote>
                                       </td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Vascular Disorders</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  Hemorrhage<footnote>Hemorrhage includes tumor hemorrhage, upper gastrointestinal hemorrhage, gastrointestinal hemorrhage, hemoptysis, esophageal hemorrhage, hematuria, gastric hemorrhage, epistaxis, tracheal hemorrhage, gingival bleeding, pulmonary hemorrhage, procedural hemorrhage, rectal hemorrhage, stoma site hemorrhage.</footnote>
                                       </td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table width="85%">
                                 <caption>Table 5:	Laboratory Abnormalities Worsening From Baseline Occurring in ≥10% of Patients Receiving TEVIMBRA in RATIONALE-302</caption>
                                 <col width="24%" align="left" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <col width="19%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th colspan="2" styleCode="Botrule Rrule">TEVIMBRA<footnote ID="Tb3fta">The denominator used to calculate the rate varied from 136 to 240 based on the number of patients with a baseline value and at least one post-treatment value.</footnote>
                                       </th>
                                       <th colspan="2" styleCode="Botrule Rrule">ICC<footnoteRef IDREF="Tb3fta"/>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Laboratory Abnormality</th>
                                       <th styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                       <th styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Glucose increased </td>
                                       <td styleCode="Rrule">46</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">40</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Sodium decreased</td>
                                       <td styleCode="Rrule">34</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">36</td>
                                       <td styleCode="Rrule">8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Albumin decreased</td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">37</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Alkaline phosphatase increased</td>
                                       <td styleCode="Rrule">32</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">0.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  AST increased</td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  ALT increased</td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Phosphate decreased</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Creatine kinase increased</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Potassium decreased</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Bilirubin increased</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">0.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Glucose decreased</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.4</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="5" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Hemoglobin decreased</td>
                                       <td styleCode="Rrule">45</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">61</td>
                                       <td styleCode="Rrule">10</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Lymphocytes decreased</td>
                                       <td styleCode="Rrule">43</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">60</td>
                                       <td styleCode="Rrule">28</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Platelets decreased</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0.9</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  Leukocytes decreased</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.8</td>
                                       <td styleCode="Rrule">66</td>
                                       <td styleCode="Rrule">31</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="525b6586-eb0a-4790-a134-64829ee8d71e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment of Previously Untreated Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (G/GEJ)</content>
                              </paragraph>
                              <paragraph>The safety of TEVIMBRA in combination with chemotherapy was evaluated in RATIONALE-305, a randomized, multicenter, double-blind, placebo-controlled trial in patients with previously untreated unresectable or metastatic G/GEJ adenocarcinoma <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>Patients were randomized (1:1) to receive either TEVIMBRA 200 mg by intravenous infusion over 30-60 minutes every 3 weeks or placebo plus a platinum and fluoropyrimidine-based chemotherapy. The chemotherapy regimens consisted of:</paragraph>
                              <list listType="unordered">
                                 <item>Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 for up to 6 cycles and capecitabine 1000 mg/m<sup>2</sup> orally twice daily for 14 consecutive days of every 3-week cycle.</item>
                              </list>
                              <paragraph>or</paragraph>
                              <list listType="unordered">
                                 <item>Cisplatin 80 mg/m<sup>2</sup> IV, Day 1, and 5-FU (5-fluorouracil) 800 mg/m<sup>2</sup>/day IV continuous infusion over 24 hours daily Day 1-5, every 3 weeks for up to 6 cycles. </item>
                              </list>
                              <paragraph>Patients were treated until disease progression or unacceptable toxicity. The median duration of exposure was 5.91 months (range: 0.1 to 47 months) in TEVIMBRA-treated patients.</paragraph>
                              <paragraph>Serious adverse reactions occurred in 42% of patients receiving TEVIMBRA in combination with chemotherapy. The most frequent serious adverse drug reactions (≥2%) were pneumonia (3.6%), decreased platelet count (3.2%), gastrointestinal hemorrhage (3%), and colitis (2.2%). Fatal adverse reactions occurred in 4.2% of patients who received TEVIMBRA in combination with chemotherapy; events occurring in 2 or more patients were death, sepsis, pneumonia, pulmonary embolism, and respiratory failure.</paragraph>
                              <paragraph>Permanent discontinuation of TEVIMBRA due to an adverse reaction occurred in 16% of patients. Adverse drug reactions which resulted in permanent discontinuation in ≥1% of patients were death, fatigue, and pneumonitis.</paragraph>
                              <paragraph>Dosage interruption of TEVIMBRA due to an adverse drug reaction occurred in 49% of patients. Adverse drug reactions which required dosage interruption in ≥2% of patients were decreased platelet count (12%), decreased neutrophil count (10%), neutropenia (6%), decreased white blood cell count (6%), increased AST (4.8%), increased ALT (3.8%), increased blood bilirubin (3%), COVID-19 (3%), thrombocytopenia (2.8%), leukopenia (2.6%), pneumonitis (2.2%), and pneumonia (2%).</paragraph>
                              <paragraph>The most common (≥20%) adverse reactions, including laboratory abnormalities, for TEVIMBRA in combination with chemotherapy were nausea, fatigue, decreased appetite, anemia, peripheral sensory neuropathy, vomiting, decreased platelet count, decreased neutrophil count, increased aspartate aminotransferase, diarrhea, abdominal pain, increased alanine aminotransferase, white blood cell count decreased, decreased weight, and pyrexia. </paragraph>
                              <paragraph>Adverse reactions and laboratory abnormalities are listed in Table 6 and Table 7, respectively.</paragraph>
                              <table width="75%">
                                 <caption>Table 6: Adverse Reactions (≥10%) in Patients with G/GEJ Receiving TEVIMBRA + Chemotherapy with a Difference Between Arms of ≥5% for All Grades or ≥2% for Grades 3 and 4 vs Placebo + Chemotherapy in RATIONALE-305</caption>
                                 <col width="40%" align="left" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <col width="15%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Adverse Drug Reaction</th>
                                       <th styleCode="Rrule" colspan="2">TEVIMBRA + Chemotherapy<br/>(N=498)</th>
                                       <th styleCode="Rrule" colspan="2">Placebo + Chemotherapy<br/>(N=494)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                       <th styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pyrexia</td>
                                       <td styleCode="Rrule">20</td>
                                       <td styleCode="Rrule">1.6</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0.6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash<footnote ID="t4fa">Represents a composite of multiple, related preferred terms. </footnote>
                                       </td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">1.6</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">0.2</td>
                                       <td styleCode="Rrule">3.2</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Endocrine Disorders</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Hypothyroidism<footnoteRef IDREF="t4fa"/>
                                       </td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">0.2</td>
                                       <td styleCode="Rrule">2.8</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6ca5823a-0213-43b5-8ae6-abcb0bf2f398"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Clinically Important Adverse Reactions Occurring in Less Than 10% include</content>: 										</paragraph>
                              <paragraph>Stomatitis, infusion-related reaction, dyspnea, hepatitis, hyperthyroidism, pneumonitis, hyperglycemia, myalgia, diabetes mellitus, pancreatitis, arthritis, Sjogren's syndrome, thyroiditis, adrenal insufficiency, hypophysitis, myasthenia gravis, uveitis, myocarditis, pericarditis, colitis, vitiligo, myositis, and nephritis.</paragraph>
                              <table width="80%">
                                 <caption>Table 7: Select Laboratory Abnormalities Worsening from Baseline Occurring in ≥10% of Patients Receiving TEVIMBRA + Chemotherapy with a Difference Between Arms of ≥5% for All Grades or ≥2% for Grades 3 and 4 vs Placebo + Chemotherapy in RATIONALE-305 </caption>
                                 <col width="32%" align="left" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <col width="17%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Laboratory Abnormality</th>
                                       <th styleCode="Rrule" colspan="2">TEVIMBRA + Chemotherapy<footnote ID="t5fa">The denominator used to calculate the rate varied from 480 to 494 based on the number of patients with a baseline value and at least one post-treatment value.</footnote>
                                          <br/>(N=498)</th>
                                       <th styleCode="Rrule" colspan="2">Placebo + Chemotherapy<footnoteRef IDREF="t5fa"/>
                                          <br/>(N=494)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                       <th styleCode="Rrule">All Grades<br/>(%)</th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/>(%)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="5">Abbreviations: ALT, alanine aminotransferase; AST, aspartate amino transferase.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">AST increased</td>
                                       <td styleCode="Rrule">58</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">56</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sodium decreased</td>
                                       <td styleCode="Rrule">42</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">36</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ALT increased</td>
                                       <td styleCode="Rrule">41</td>
                                       <td styleCode="Rrule">4.8</td>
                                       <td styleCode="Rrule">36</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Potassium decreased</td>
                                       <td styleCode="Rrule">33</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">28</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Lymphocytes decreased</td>
                                       <td styleCode="Rrule">53</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">46</td>
                                       <td styleCode="Rrule">9</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="75296c7e-f5ea-4581-9947-f354e40423a5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Clinically Important Laboratory Abnormalities Occurring in &lt;20% include</content>: 										</paragraph>
                              <paragraph>Creatinine increased, potassium increased, glucose decreased, sodium increased, lymphocytes increased, hemoglobin increased. </paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="2f7621fb-96a4-45b1-9b60-1993521702cb"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="78c9ac9f-5c6b-413c-a996-3f957178e8a9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="44471cf9-b1ef-4e34-b9fd-575fb97cf228"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on its mechanism of action, TEVIMBRA can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>. There are no available data on the use of TEVIMBRA in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. Human IgG4 immunoglobulins (IgG4) are known to cross the placental barrier; therefore, tislelizumab-jsgr has the potential to be transmitted from the mother to the developing fetus. Advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="9ac990c4-51fe-4e87-8ed2-3c0a27d47318"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                           <component>
                              <section>
                                 <id root="fb202335-84f0-450b-bb52-9823293bb3d2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Animal reproduction studies have not been conducted with TEVIMBRA to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering TEVIMBRA during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to tislelizumab-jsgr may increase the risk of developing immune-mediated disorders or altering the normal immune response.</paragraph>
                                 </text>
                                 <effectiveTime value="20250306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="c9011f67-2151-450e-8ad9-c43bb19057b0"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="72427358-d277-4f05-9074-01f6e9677597"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of tislelizumab-jsgr in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose of TEVIMBRA.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="e5906490-e681-4add-9a68-4b79bf41eea5"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>TEVIMBRA can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="b73737f5-52fe-4b52-a579-ec5adde3b629"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating TEVIMBRA <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ee99202f-55cc-43f1-a9e4-a92dac7d833f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                           <component>
                              <section>
                                 <id root="2102b7a3-9654-4a54-9bd1-16fb60ae1bfa"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with TEVIMBRA and for 4 months after the last dose of TEVIMBRA.</paragraph>
                                 </text>
                                 <effectiveTime value="20250306"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="371a5f4b-751f-4781-a7e1-f0d6419f78b7"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of TEVIMBRA have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="624dfc38-1bb9-43d9-80d1-2615814846d3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text/>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="de266c56-ae0c-4e32-b2ad-d9e0d2d0d9a2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">TEVIMBRA as a Single Agent</content>
                              </paragraph>
                              <paragraph>Of the 255 patients who were treated with TEVIMBRA for previously treated unresectable or metastatic ESCC in the clinical study RATIONALE-302, 98 (38%) were 65 years and older and 13 (5%) were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="aab3053a-cc8b-4bba-bb7f-1b8426d552d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">TEVIMBRA in Combination with Chemotherapy</content>
                              </paragraph>
                              <paragraph>Of the 324 patients who were treated with TEVIMBRA and platinum-containing chemotherapy as first-line treatment for unresectable advanced or metastatic ESCC in the clinical study RATIONALE-306, 149 (46%) were 65 years and older and 13 (4%) were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients. </paragraph>
                              <paragraph>Of the 498 patients who were treated with TEVIMBRA in combination with platinum-containing chemotherapy for G/GEJ adenocarcinoma in the clinical study RATIONALE-305, 161 (32%) were 65 years and older, and 28 (6%) were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="e2a16eca-d534-4191-813a-80244c1fa2ba"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Tislelizumab-jsgr is a programmed death receptor-1 (PD-1)–blocking antibody. Tislelizumab-jsgr is an Fc-engineered humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 147 kDa. Tislelizumab-jsgr is produced in recombinant Chinese hamster ovary (CHO) cells.</paragraph>
                  <paragraph>TEVIMBRA (tislelizumab-jsgr) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for intravenous use, supplied in single-dose vials. Each vial contains 100 mg of tislelizumab-jsgr monoclonal antibody in 10 mL of solution, with a concentration of 10 mg/mL, and is formulated in: citric acid monohydrate (4.2 mg), histidine (17.2 mg), L-histidine hydrochloride monohydrate (8.2 mg), polysorbate 20 (2 mg), sodium citrate (59.3 mg), trehalose (650.4 mg), and Water for Injection, USP. The pH is 6.5.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="53158863-3d3f-448a-9bdf-81a4cd6cb169"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250306"/>
               <component>
                  <section ID="S12.1">
                     <id root="7f58ee1d-9bbe-4f82-9dac-f37ba6c3ad63"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action </title>
                     <text>
                        <paragraph>Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.</paragraph>
                        <paragraph>Tislelizumab-jsgr binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Tislelizumab-jsgr decreased tumor growth in xenograft models and a human PD-1 transgenic mouse model.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="7944f298-2bac-4bc7-aa1a-4d25d6f618d0"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The tislelizumab-jsgr exposure-response relationship for efficacy and safety and time course of pharmacodynamic response has not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="321d4e62-1827-476f-868c-0707a6e7b2cc"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Pharmacokinetic parameters are presented as geometric mean (% CV) unless otherwise specified.</paragraph>
                        <paragraph>The peak concentration (C<sub>max</sub>) and area under the plasma concentration versus time curve (AUC) of tislelizumab-jsgr increased dose proportionally in the dose range of 0.5 (0.2 times the approved recommended dosage in a 70 kg patient) to 10 mg/kg (3.5 times the approved recommended dosage in a 70 kg patient).</paragraph>
                        <paragraph>The steady-state AUC<sub>tau</sub> of tislelizumab-jsgr is 1,283 mcg/mL∙day (28.7%) and the C<sub>max</sub> is 110 mcg/mL (22.2%) following the approved recommended dosage. Steady-state concentration of tislelizumab-jsgr is reached after 12 weeks of repeated dosing with an every 3-week regimen and the systemic accumulation was 2.14-fold.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="abc53f46-11c5-4736-b13c-bcae01e0a8df"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The tislelizumab-jsgr steady-state total volume of distribution is 6.42 L (32.6%).</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="73222f4e-01c8-4d4c-9f99-9970972d1235"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The tislelizumab-jsgr total clearance is 0.153 L/day (29.5%) and the terminal half-life (t<sub>½</sub>) is 24 days (31%).</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0ef0458d-1dfb-45b3-92dd-17b6adf1ddc1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of tislelizumab-jsgr were observed based on age (range: 18 to 90 years), weight (range: 32 to 130 kg), race (White, Asian, or Black), mild to moderate renal impairment (CLcr ≥30 mL/min, estimated by Cockcroft-Gault), mild to moderate hepatic impairment (total bilirubin ≤3 times ULN and any AST, estimated by NCI criteria). The effect of severe hepatic impairment (total bilirubin &gt;3 times ULN and any AST), severe renal impairment (CLcr 15-29 mL/min), or end-stage renal disease (CLcr &lt;15 mL/min) on the pharmacokinetics of tislelizumab-jsgr is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="6a40bf4c-ce5b-413e-b2c7-305857b2ac56"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6	Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of tislelizumab-jsgr products.</paragraph>
                        <paragraph>In patients who received tislelizumab-jsgr in RATIONALE-306 for up to 26 months, the incidence of anti-tislelizumab antibodies was 22% (66/300). Among the anti-tislelizumab antibody-positive patients, the incidence of neutralizing antibodies was 1.5% (1/66). </paragraph>
                        <paragraph>In patients who received tislelizumab-jsgr in RATIONALE-302 for up to 22 months, the incidence of anti-tislelizumab antibodies was 14.5% (32/221). Among the anti-tislelizumab antibody-positive patients, the incidence of neutralizing antibodies was 3.1% (1/32).</paragraph>
                        <paragraph>In patients who received tislelizumab-jsgr in RATIONALE-305 throughout the treatment period and in the ADA analysis set, the incidence of anti-tislelizumab antibodies was 22.7% (108/475). Among the anti-tislelizumab antibody-positive patients, the incidence of neutralizing antibodies was 5.6% (6/108). </paragraph>
                        <paragraph>There was no significant effect of anti-drug antibodies on the pharmacokinetics of tislelizumab-jsgr. The effect of anti-drug antibodies on pharmacodynamics, safety, or effectiveness of tislelizumab-jsgr has not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="96e64148-bff1-4816-9624-494025860ee7"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250306"/>
               <component>
                  <section ID="S13.1">
                     <id root="b5607d55-41a0-416a-85ac-de5f94b2606d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>No studies have been performed to assess the potential of tislelizumab-jsgr for carcinogenicity or genotoxicity.</paragraph>
                        <paragraph>In a 3-month repeat-dose toxicology study in cynomolgus monkeys, there were no notable effects in the male and female reproductive organs; however, most animals in the study were not sexually mature.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="f658d3d3-70a0-4fbf-bc8e-493075053cb4"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In animal models, inhibition of PD-L1/PD-1 signaling resulted in an increased severity of some infections and enhanced inflammatory responses. <content styleCode="italics">Mycobacterium tuberculosis</content>–infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-1 blockade using a primate anti–PD-1 antibody was also shown to exacerbate <content styleCode="italics">M. tuberculosis</content> infection in rhesus macaques. PD-L1 and PD-1 knockout mice have also shown decreased survival following infection with lymphocytic choriomeningitis virus.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="39458131-9b1d-4822-8081-06f44b79da06"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250306"/>
               <component>
                  <section ID="S14.1">
                     <id root="4a8a1eaf-368f-464a-9662-8383967ff86f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	Esophageal Squamous Cell Carcinoma</title>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="6ae2bb19-6823-47f4-99d3-5d56f6c2fd1b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>First-line Treatment of Unresectable or Metastatic Esophageal Carcinoma (ESCC) in Patients Whose Tumors Express PD-L1 (≥1)</paragraph>
                              <paragraph>The efficacy of TEVIMBRA, in combination with chemotherapy, was evaluated in RATIONALE-306 (NCT03783442), a global, randomized, placebo-controlled, double-blind study in patients with unresectable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).</paragraph>
                              <paragraph>Patients were enrolled regardless of their PD-L1 expression level. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on both tumor and tumor-associated immune cells (Tumor Area Positivity or TAP). A retrospective scoring of tumor PD-L1 status using Combined Positive Score (CPS) was also conducted using the PD-L1–stained tumor specimens used for randomization.</paragraph>
                              <paragraph>Patients should not have received prior systemic therapy for advanced or metastatic disease. A treatment-free interval of at least 6 months was required if there was prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy. The trial excluded patients who had active leptomeningeal disease or uncontrolled brain metastasis, active autoimmune disease, a medical condition requiring systemic corticosteroids or immunosuppressants, or evidence of fistula or complete esophageal obstruction not amenable to treatment.</paragraph>
                              <paragraph>Patients were randomized (1:1) to receive either TEVIMBRA 200 mg every 3 weeks or placebo in combination with investigator's choice of chemotherapy (ICC) on a 21-day cycle. Patients received TEVIMBRA until disease progression assessed by the investigator per RECIST v1.1, or until unacceptable toxicity. The chemotherapy doublet regimen consists of:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Platinum (cisplatin [60 to 80 mg/m<sup>2</sup> IV, on Day 1] or oxaliplatin [130 mg/m<sup>2</sup> IV, on Day 1]) and a fluoropyrimidine (fluorouracil [750 to 800 mg/m<sup>2</sup> IV, on Days 1 to 5] or capecitabine [1000 mg/m<sup>2</sup> orally twice daily, on Days 1 to 14]),<br/>or</item>
                              </list>
                              <paragraph/>
                              <list listType="unordered" styleCode="disc">
                                 <item>Platinum (cisplatin [60 to 80 mg/m<sup>2</sup> IV, on Day 1 or 2] or oxaliplatin [130 mg/m<sup>2</sup> IV, on Day 1 or 2]) and (paclitaxel 175 mg/m<sup>2</sup> IV, on Day 1)</item>
                              </list>
                              <paragraph>Cross-over between treatment arms or between fluoropyrimidine and paclitaxel during the study treatment period was not allowed.</paragraph>
                              <paragraph>Patient randomization was stratified by geographic region (Asia [excluding Japan] versus Japan versus Rest of World), prior definitive therapy (yes versus no), and investigator choice of chemotherapy (ICC; platinum with fluoropyrimidine versus platinum with paclitaxel).</paragraph>
                              <paragraph>Tumor assessments were performed every 6 weeks for the first 48 weeks, then every 9 weeks thereafter.</paragraph>
                              <paragraph>The primary efficacy outcome measure was overall survival (OS) in the Intent-to-Treat (ITT) population. Secondary outcome measures included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) as assessed by the investigator per RECIST v1.1. Additional analyses of efficacy outcome measures were also conducted based on PD-L1 TAP ≥1% and CPS ≥1.</paragraph>
                              <paragraph>A total of 649 patients were randomized. The trial population characteristics were median age 64 years (range: 26 to 84 years), 48% were ≥65 years of age, 87% were male, 75% were Asian, and 24% were White. Eighty-six percent had metastatic disease and 14% had locally advanced disease; 99.8% of patients had histological confirmation of squamous cell carcinoma. Baseline ECOG performance status was 0 (33%) or 1 (67%). Thirty-four percent of patients had tumors that expressed PD-L1 TAP ≥10%, 74% had PD-L1 TAP ≥1%, and 74% had PD-L1 CPS ≥1. Fifty-five percent of patients received platinum (cisplatin or oxaliplatin) and paclitaxel-containing regimens, and 45% received platinum (cisplatin or oxaliplatin) and fluoropyrimidine-containing regimens.</paragraph>
                              <paragraph>RATIONALE-306 demonstrated a statistically significant improvement in OS for patients randomized to TEVIMBRA in combination with chemotherapy compared to placebo in combination with chemotherapy. Exploratory analysis of OS in the population with TAP &lt;1% population and in the CPS &lt;1 population showed hazard ratios of 1.34 (95% CI 0.73, 2.46) and 1.52 (95% CI 0.81, 2.84), respectively, indicating that the improvement in the ITT population was primarily attributed to the results observed in the subgroup of patients with PD-L1 ≥1.</paragraph>
                              <paragraph>Efficacy results are shown in Table 8, Figure 1, and Figure 2.</paragraph>
                              <table width="80%">
                                 <caption>Table 8: Efficacy results in RATIONALE-306</caption>
                                 <col width="20%" align="left" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="20%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Endpoint</th>
                                       <th styleCode="Rrule">TEVIMBRA + Chemotherapy<br/>(N=231)</th>
                                       <th styleCode="Rrule">Placebo + Chemotherapy<br/>(N=250)</th>
                                       <th styleCode="Rrule">TEVIMBRA + Chemotherapy<br/>(N=233)</th>
                                       <th styleCode="Rrule">Placebo + Chemotherapy<br/>(N=247)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" colspan="2" align="center">PD-L1 TAP ≥1%</th>
                                       <th styleCode="Rrule" colspan="2">PD-L1 CPS ≥1</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left">CI, confidence interval; HR, hazard ratio.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Overall Survival (OS)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Deaths n (%)</td>
                                       <td styleCode="Rrule">141 (61)</td>
                                       <td styleCode="Rrule">177 (70.8)</td>
                                       <td styleCode="Rrule">141 (61)</td>
                                       <td styleCode="Rrule">175 (71)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median (months)<footnote ID="t8ft1">Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.</footnote> (95% CI)</td>
                                       <td styleCode="Rrule">16.8 (15.3, 20.8)</td>
                                       <td styleCode="Rrule">9.6 (8.9, 11.8)</td>
                                       <td styleCode="Rrule">16.8 (15.3, 20.8)</td>
                                       <td styleCode="Rrule">9.6 (8.9, 11.8)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">HR<footnote ID="t8ft2">Estimated by Cox proportional hazards model.</footnote> (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.66 (0.53, 0.82)</td>
                                       <td styleCode="Rrule" colspan="2">0.65 (0.52,0.81)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Progression-Free Survival (PFS)</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Events, n (%)</td>
                                       <td styleCode="Rrule">152 (66)</td>
                                       <td styleCode="Rrule">199 (80)</td>
                                       <td styleCode="Rrule">153 (66)</td>
                                       <td styleCode="Rrule">195 (79)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median (months)<footnoteRef IDREF="t8ft1"/> (95% CI)</td>
                                       <td styleCode="Rrule">7.2 (6.8, 8.5)</td>
                                       <td styleCode="Rrule">5.5 (4.5, 5.8)</td>
                                       <td styleCode="Rrule">7.1 (6.8, 8.3)</td>
                                       <td styleCode="Rrule">5.5 (4.5, 5.8)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">HR<footnoteRef IDREF="t8ft2"/> (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.56 (0.45, 0.70)</td>
                                       <td styleCode="Rrule" colspan="2">0.57 (0.46, 0.71)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Objective Response Rate (ORR)<footnote ID="t8ft3">Confirmed responses.</footnote>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Responders, n</td>
                                       <td styleCode="Rrule">134</td>
                                       <td styleCode="Rrule">90</td>
                                       <td styleCode="Rrule">134</td>
                                       <td styleCode="Rrule">89</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ORR, %</td>
                                       <td styleCode="Rrule">58</td>
                                       <td styleCode="Rrule">36</td>
                                       <td styleCode="Rrule">58</td>
                                       <td styleCode="Rrule">36</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">95% CI<footnote>Exact Clopper-Person-2-sided CI.</footnote>
                                       </td>
                                       <td styleCode="Rrule">(51, 65)</td>
                                       <td styleCode="Rrule">(30, 42)</td>
                                       <td styleCode="Rrule">(51, 64)</td>
                                       <td styleCode="Rrule">(30, 42)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Complete response (CR), n (%)</td>
                                       <td styleCode="Rrule">11 (4.8)</td>
                                       <td styleCode="Rrule">5 (2)</td>
                                       <td styleCode="Rrule">11 (4.7)</td>
                                       <td styleCode="Rrule">5 (2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Partial response, n (%)</td>
                                       <td styleCode="Rrule">123 (53)</td>
                                       <td styleCode="Rrule">85 (34)</td>
                                       <td styleCode="Rrule">123 (53)</td>
                                       <td styleCode="Rrule">84 (34)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Duration of Response (DoR)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Median DoR (months)<footnoteRef IDREF="t8ft1"/> (95% CI)</td>
                                       <td styleCode="Rrule">7.2 (6.2, 9.6)</td>
                                       <td styleCode="Rrule">5.7 (4.4, 7.3)</td>
                                       <td styleCode="Rrule">7.6 (6.6, 9.7)</td>
                                       <td styleCode="Rrule">5.6 (4.4, 7.3)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 1: Kaplan-Meier Curve for Overall Survival in RATIONALE-306 (PD-L1 TAP ≥1%)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM1"/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 2: Kaplan-Meier Curve for Overall Survival in RATIONALE-306 (PD-L1 CPS ≥1)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM2"/>
                              </paragraph>
                              <paragraph>Efficacy results from the exploratory retrospective analysis with CPS scoring were generally consistent with the efficacy results for TAP subgroups detailed in Table 8 and Figure 1.</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                           <component>
                              <observationMedia ID="MM1">
                                 <text>Figure 1</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="tevimbra-01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Figure 2</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="tevimbra-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="85e7a77f-fc2f-4c58-a1e8-84e4a7a2afc1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Previously Treated Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)</content>
                              </paragraph>
                              <paragraph>RATIONALE-302 (NCT03430843) was a multicenter, randomized (1:1), open-label trial in 512 adult patients with unresectable advanced or metastatic ESCC who progressed on or after prior systemic chemotherapy.</paragraph>
                              <paragraph>Patients were enrolled regardless of their tumor PD-L1 expression level. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on both tumor and tumor-associated immune cells (TAP). The trial excluded patients who received a prior immune checkpoint inhibitor, had brain or leptomeningeal metastases that were symptomatic or required treatment, active autoimmune disease, a medical condition requiring systemic corticosteroids or immunosuppressants, or apparent tumor invasion of organs adjacent to the esophageal tumor.</paragraph>
                              <paragraph>Patients were randomized (1:1) to receive either TEVIMBRA 200 mg every 3 weeks or investigator's choice of chemotherapy (ICC), all given intravenously: paclitaxel 135-175 mg/m<sup>2</sup> every 3 weeks or 80 to 100 mg/m<sup>2</sup> weekly, docetaxel 75 mg/m<sup>2</sup> every 3 weeks, or irinotecan 125 mg/m<sup>2</sup> on Days 1 and 8 of every 3-week cycle. Patients were treated until disease progression assessed by the investigator or unacceptable toxicity.</paragraph>
                              <paragraph>Randomization was stratified by geographic region (Asia [excluding Japan] vs Japan vs US/EU), ECOG performance status (0 vs 1), and ICC option. Tumor assessments were conducted every 6 weeks for the first 6 months, then every 9 weeks until disease progression.</paragraph>
                              <paragraph>The major efficacy outcome measure was overall survival (OS) in the Intent-to-Treat (ITT) population. Additional efficacy outcome measures were investigator-assessed progression-free survival (PFS), overall response rate (ORR), and duration of response (DOR) per RECIST v1.1.</paragraph>
                              <paragraph>A total of 512 patients were enrolled and randomized to TEVIMBRA (n=256) or ICC (n=256) (irinotecan [46%], paclitaxel [33%], or docetaxel [21%]). Of the 512 patients, 142 (28%) had PD-L1 ≥10%, 222 (43%) had PD-L1 &lt;10%, and 148 (29%) had unknown baseline PD-L1 status.</paragraph>
                              <paragraph>The trial population characteristics were: median age of 62 years (range: 35 to 86), 38% age ≥65; 84% male; 19% White and 80% Asian; 95% had metastatic disease. All patients had received at least one prior anti-cancer systemic therapy. Baseline ECOG performance status was 0 (25%) or 1 (75%).</paragraph>
                              <paragraph>RATIONALE-302 demonstrated a statistically significant improvement in OS for patients randomized to TEVIMBRA as compared with ICC. OS results by PD-L1 CPS level (&lt;1 and ≥1) were not studied.</paragraph>
                              <paragraph>Efficacy results are shown in Table 9 and Figure 3.</paragraph>
                              <table width="75%">
                                 <caption>Table 9:	Efficacy Results in RATIONALE-302 in ITT Population</caption>
                                 <col width="40%" align="left" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <col width="35%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Endpoint</th>
                                       <th styleCode="Rrule">TEVIMBRA<br/>(N=256)</th>
                                       <th styleCode="Rrule">ICC<br/>(N=256)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">CI = confidence interval, ORR = objective response rate.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Overall Survival</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Deaths n (%)</td>
                                       <td styleCode="Rrule">197 (77)</td>
                                       <td styleCode="Rrule">213 (83.2)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Median (months)<footnote ID="Tb4fta">Estimated using Kaplan-Meier method.</footnote> (95% CI)</td>
                                       <td styleCode="Rrule">8.6 (7.5, 10.4)</td>
                                       <td styleCode="Rrule">6.3 (5.3, 7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Hazard ratio<footnote ID="Tb4ftb">Based on Cox regression model stratified by baseline ECOG status and ICC option.</footnote> (95% CI) </td>
                                       <td colspan="2" styleCode="Rrule">0.7 (0.57, 0.85)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  p-value<footnote>One-sided p-value based on log-rank test stratified by ECOG performance status and ICC option.</footnote>
                                       </td>
                                       <td colspan="2" styleCode="Rrule">0.0001</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Progression-Free Survival</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Disease progression or death (%)</td>
                                       <td styleCode="Rrule">223 (87.1)</td>
                                       <td styleCode="Rrule">180 (70.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Median (months)<footnoteRef IDREF="Tb4fta"/> (95% CI)</td>
                                       <td styleCode="Rrule">1.6 (1.4, 2.7)</td>
                                       <td styleCode="Rrule">2.1 (1.5, 2.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Hazard ratio<footnoteRef IDREF="Tb4ftb"/> (95% CI)</td>
                                       <td colspan="2" styleCode="Rrule">0.83 (0.67, 1.01)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Objective Response Rate</content>
                                          <footnote>Confirmed response.</footnote>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  ORR (%) (95% CI) </td>
                                       <td styleCode="Rrule">15.2 (11.1, 20.2)</td>
                                       <td styleCode="Rrule">6.6 (3.9, 10.4)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Complete response n (%) </td>
                                       <td styleCode="Rrule">5 (2)</td>
                                       <td styleCode="Rrule">1 (0.4)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Partial response n (%)</td>
                                       <td styleCode="Rrule">34 (13.3)</td>
                                       <td styleCode="Rrule">16 (6.3)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Duration of Response</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  Median (months)<footnoteRef IDREF="Tb4fta"/> (95% CI)</td>
                                       <td styleCode="Rrule">10.3 (6.5, 13.2)</td>
                                       <td styleCode="Rrule">6.3 (2.8, 8.5)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 3: Kaplan-Meier Curve for Overall Survival in RATIONALE-302 (ITT)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM3"/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Figure 3</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="tevimbra-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="371e0b34-73b0-44d2-9376-d7923b8bf4e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	Gastric Cancer </title>
                     <effectiveTime value="20250306"/>
                     <component>
                        <section>
                           <id root="546e29e7-302f-453f-a3b8-0df46bbd1fb4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Previously Untreated, Unresectable, or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma in Patients Whose Tumors Express PD-L1 (≥1)</content>
                              </paragraph>
                              <paragraph>RATIONALE-305 (NCT03777657) was a randomized, multicenter, placebo-controlled, double-blind trial in patients with HER2-negative previously untreated unresectable or metastatic G/GEJ adenocarcinoma. </paragraph>
                              <paragraph>Patients were enrolled regardless of their tumor PD-L1 expression level, which was evaluated prospectively at a central laboratory using the VENTANA PD-L1 (SP263) assay that identified PD-L1 staining on both tumor and tumor-associated immune cells (TAP). A retrospective scoring of tumor PD-L1 status using Combined Positive Score (CPS) was also conducted using the PD-L1-stained tumor specimens used for randomization.</paragraph>
                              <paragraph>The trial excluded patients who had active leptomeningeal disease or uncontrolled brain metastasis, and patients with active autoimmune disease or history of autoimmune diseases, or a medical condition requiring systemic corticosteroids or immunosuppressants.</paragraph>
                              <paragraph>Patients were randomized to receive either TEVIMBRA 200 mg every 3 weeks or placebo in combination with investigator's choice of chemotherapy on a 21-day cycle. TEVIMBRA (or placebo) was administered until disease progression or unacceptable toxicity.</paragraph>
                              <paragraph>The chemotherapy doublets regimen consisted of:</paragraph>
                              <list listType="unordered">
                                 <item>CAPOX: Oxaliplatin 130 mg/m<sup>2</sup> IV on Day 1 for up to 6 cycles and capecitabine 1000 mg/m<sup>2</sup> orally twice daily for 14 consecutive days. Capecitabine treatment could be continued beyond 6 cycles.</item>
                              </list>
                              <paragraph>or</paragraph>
                              <list listType="unordered">
                                 <item>FP: Cisplatin 80 mg/m<sup>2</sup> IV, Day 1, and 5-FU 800 mg/m<sup>2</sup>/day IV continuous infusion over 24 hours daily Day 1-5. Cisplatin and 5-FU were given for up to 6 cycles.</item>
                              </list>
                              <paragraph>Cross-over between treatment arms was not allowed.</paragraph>
                              <paragraph>Patient randomization was stratified by geographic region (China [including Taiwan], vs Japan and South Korea vs rest of the world, including US and Europe); PD-L1 expression (PD-L1 TAP score ≥5% vs PD-L1 TAP score &lt;5%); presence of peritoneal metastasis (yes vs no); and ICC option (oxaliplatin plus capecitabine vs cisplatin plus 5-FU).</paragraph>
                              <paragraph>Tumor assessments were performed every 6 weeks for the first 48 weeks and thereafter approximately every 9 weeks.</paragraph>
                              <paragraph>The primary efficacy outcome measures were OS in the PD-L1 TAP score ≥5% population and in the Intent-to-Treat (ITT) population. Secondary outcome measures included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) as assessed by the investigator per RECIST v1.1. Additional analyses of efficacy outcome measures were also conducted based on PD-L1 TAP ≥1% and CPS ≥1.</paragraph>
                              <paragraph>A total of 997 patients were randomized. The trial population characteristics were median age 61 years (range: 23 to 86 years), 35% ≥65 years of age, 69% male; 75% Asian, 22% White, and 0% Black or African American. Eighty percent had primary stomach tumor; 89% had PD-L1 TAP ≥1% and 86% had PD-L1 CPS ≥1, and 99% of patients had metastatic disease at baseline. Baseline ECOG performance status was 0 (32%) or 1 (68%). Ninety-three percent of patients received CAPOX and 7% received FP.</paragraph>
                              <paragraph>RATIONALE-305 demonstrated a statistically significant improvement in OS for patients randomized to TEVIMBRA in combination with chemotherapy compared with placebo plus chemotherapy in the PD-L1 TAP ≥5% population and in the ITT population. Exploratory analyses of OS in the TAP &lt;1% population and in the CPS &lt;1 population showed hazard ratios of 0.98 (95% CI: 0.64, 1.50) and 1.01 (95% CI: 0.66, 1.52) respectively, indicating that the improvement in the ITT population was primarily attributed to the results observed in the subgroup of patients with PD-L1 ≥1.</paragraph>
                              <paragraph>Efficacy results are summarized in Table 10, Figure 4, and Figure 5.</paragraph>
                              <table width="80%">
                                 <caption>Table 10: Efficacy Results in RATIONALE-305 </caption>
                                 <col width="20%" align="left" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule" rowspan="2">Endpoint</th>
                                       <th styleCode="Rrule">TEVIMBRA + Chemotherapy<br/>(N=432)</th>
                                       <th styleCode="Rrule">Placebo + Chemotherapy<br/>(N=453)</th>
                                       <th styleCode="Rrule">TEVIMBRA + Chemotherapy<br/>(N=420)</th>
                                       <th styleCode="Rrule">Placebo + Chemotherapy<br/>(N=434)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Rrule" colspan="2" align="center">PD-L1 TAP ≥1%</th>
                                       <th styleCode="Rrule" colspan="2">PD-L1 CPS ≥1</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left">Abbreviations: CI, confidence interval; HR, hazard ratio; ORR, objective response rate.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Overall Survival</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Deaths n (%)</td>
                                       <td styleCode="Rrule">318 (74)</td>
                                       <td styleCode="Rrule">370 (82)</td>
                                       <td styleCode="Rrule">308 (73)</td>
                                       <td styleCode="Rrule">356 (82)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median (months)<footnote ID="t7fa">Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.</footnote> (95% CI)</td>
                                       <td styleCode="Rrule">15.0 (13.3, 16.7)</td>
                                       <td styleCode="Rrule">12.8 (12.1, 14.1)</td>
                                       <td styleCode="Rrule">15.1 (13.6, 17.2)</td>
                                       <td styleCode="Rrule">12.9 (12.1, 14.1)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">HR<footnote ID="t7fb">Estimated by Cox proportional hazards model.</footnote> (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.78 (0.67, 0.90)</td>
                                       <td styleCode="Rrule" colspan="2">0.78 (0.67, 0.91)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Progression-Free Survival</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Events, n (%)</td>
                                       <td styleCode="Rrule">316 (73)</td>
                                       <td styleCode="Rrule">364 (80)</td>
                                       <td styleCode="Rrule">303 (72)</td>
                                       <td styleCode="Rrule">348 (80)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Median<footnote ID="t7fc">Based on confirmed response.</footnote> (months) (95% CI)</td>
                                       <td styleCode="Rrule">6.9 (5.7, 7.2)</td>
                                       <td styleCode="Rrule">5.9 (5.6, 6.9)</td>
                                       <td styleCode="Rrule">7.0 (5.7, 7.7)</td>
                                       <td styleCode="Rrule">6.4 (5.6, 6.9)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">HR<footnoteRef IDREF="t7fb"/> (95% CI)</td>
                                       <td styleCode="Rrule" colspan="2">0.78 (0.67, 0.91) </td>
                                       <td styleCode="Rrule" colspan="2">0.77 (0.66, 0.90)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Objective Response Rate<footnoteRef IDREF="t7fc"/>
                                          </content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ORR, n</td>
                                       <td styleCode="Rrule">206</td>
                                       <td styleCode="Rrule">186</td>
                                       <td styleCode="Rrule">204</td>
                                       <td styleCode="Rrule">183</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">ORR, %</td>
                                       <td styleCode="Rrule">48</td>
                                       <td styleCode="Rrule">41</td>
                                       <td styleCode="Rrule">49</td>
                                       <td styleCode="Rrule">42</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">95% CI (%)<footnote>Exact Clopper-Pearson 2-sided confidence interval.</footnote>
                                       </td>
                                       <td styleCode="Rrule">(43, 53)</td>
                                       <td styleCode="Rrule">(37, 46)</td>
                                       <td styleCode="Rrule">(44, 53)</td>
                                       <td styleCode="Rrule">(37, 47)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Complete response, n (%) </td>
                                       <td styleCode="Rrule">15 (3.5)</td>
                                       <td styleCode="Rrule">15 (3.3)</td>
                                       <td styleCode="Rrule">16 (3.8)</td>
                                       <td styleCode="Rrule">16 (3.7)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Partial response, n (%)</td>
                                       <td styleCode="Rrule">191 (44)</td>
                                       <td styleCode="Rrule">171 (38)</td>
                                       <td styleCode="Rrule">188 (45)</td>
                                       <td styleCode="Rrule">167 (38)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" colspan="5">
                                          <content styleCode="bold">Duration of Response</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Median (months)<footnoteRef IDREF="t7fa"/> (95% CI)</td>
                                       <td styleCode="Rrule">8.6 (7.8, 10.4)</td>
                                       <td styleCode="Rrule">7.2 (5.8, 8.3)</td>
                                       <td styleCode="Rrule">8.6 (7.8, 10.4)</td>
                                       <td styleCode="Rrule">7.2 (5.8, 8.5)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="bold">Figure 4: Kaplan-Meier Curve for Overall Survival in RATIONALE-305 (PD-L1 TAP ≥1%)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM4"/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 5: Kaplan-Meier Curve for Overall Survival in RATIONALE-305 (PD-L1 CPS ≥1)</content>
                              </paragraph>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM5"/>
                              </paragraph>
                              <paragraph>An exploratory subgroup analysis of OS in 40 patients with MSI-H tumors irrespective of PD-L1 status showed a HR of 0.66 (0.3, 1.43).</paragraph>
                           </text>
                           <effectiveTime value="20250306"/>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Figure 4</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="tevimbra-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM5">
                                 <text>Figure 5</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="tevimbra-05.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="74d6d868-f2e3-4666-8fc9-9a6677e9dd07"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250306"/>
               <component>
                  <section>
                     <id root="aaee909d-4475-46c7-a0ae-028a203493d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>TEVIMBRA injection is a clear to slightly opalescent, colorless to slightly yellow solution supplied in a carton containing one 100 mg/10 mL (10 mg/mL) single-dose vial (NDC 72579-121-01).</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5dd429e1-5d29-496d-8df7-f5a75de831a7"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <paragraph>Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.</paragraph>
                        <paragraph>Do not freeze. Do not shake.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="660f15a3-2f8a-4255-9f07-6717c28bd08e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients to read the FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <component>
                  <section>
                     <id root="7e6101a8-84b3-4f4d-b62a-1999d00e84e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Immune-Mediated Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of immune-mediated adverse reactions that may be severe or fatal, may occur after discontinuation of treatment, and may require corticosteroid treatment and interruption or discontinuation of TEVIMBRA. These reactions may include: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Pneumonitis: Advise patients to contact their healthcare provider immediately for new or worsening cough, chest pain, or shortness of breath <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>Colitis: Advise patients to contact their healthcare provider immediately for diarrhea, or severe abdominal pain <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, pain on the right side of the abdomen, or easy bruising or bleeding <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of  hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, thyroiditis, or Type 1 diabetes mellitus <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>Nephritis: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>Dermatologic Adverse Reactions: Advise patients to contact their healthcare provider immediately for any signs or symptoms of severe skin reactions, SJS, TEN, or DRESS <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>Other Immune-Mediated Adverse Reactions: 									<list listType="unordered" styleCode="circle">
                                 <item>Advise patients that immune-mediated adverse reactions can occur and may involve any organ system, and to contact their healthcare provider immediately for any new or worsening signs or symptoms <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                                 <item>Advise patients of the risk of solid organ transplant rejection and other transplant (including corneal graft) rejection and to contact their healthcare provider immediately for signs or symptoms of organ transplant rejection <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ad62d8ca-ef63-4eb4-a21b-e1c7920d6bee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infusion-Related Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f8343be2-6679-42d8-ae05-4899c3056c04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Complications of Allogeneic Hematopoietic Stem Cell Transplantation Complications</content>
                        </paragraph>
                        <paragraph>Advise patients of potential risk of post-allogeneic hematopoietic stem cell transplantation complications (HSCT) <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="f4c4762d-cc24-4c64-975f-9cea001c0c3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with TEVIMBRA and for 4 months after the last dose <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>
                           </content>, <content styleCode="italics">
                              <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a41c532a-1983-424d-8543-710c2d4f95a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with TEVIMBRA and for 4 months after the last dose <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="aa610f09-5cd8-4146-96e9-a46b039d48c8"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>BeiGene USA, Inc.<br/>San Mateo, CA 94404<br/>U.S. License No. 2232</paragraph>
                  <paragraph>TEVIMBRA<sup>®</sup> is a registered trademark owned by BeiGene, Ltd.<br/>© BeiGene, Ltd. 2025</paragraph>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section>
               <id root="6c126f73-a9f7-4cf6-a44a-fe4f71d91cc5"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="24%" align="left" valign="top"/>
                     <col width="21%" align="left" valign="top"/>
                     <col width="14%" align="left" valign="top"/>
                     <col width="41%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th colspan="4" align="center" styleCode="Lrule Rrule">Medication Guide<br/> TEVIMBRA<sup>®</sup> (teh-vim-brah)<br/>(tislelizumab-jsgr)<br/>injection</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="3" align="left" valign="top">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" valign="top">Revised: 03/2025 </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold" ID="important">What is the most important information I should know about TEVIMBRA?</content>
                              <br/>TEVIMBRA is a medicine that may treat certain cancers by working with your immune system. TEVIMBRA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.<br/>
                              <content styleCode="bold">Call or see your healthcare provider right away if you develop any new or worsening symptoms, including:<br/>Lung problems</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>new or worsening cough</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered">
                                 <item>shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered">
                                 <item>chest pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Intestinal problems</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>diarrhea (loose stools) or more bowel movements than usual</item>
                                 <item>stools that are black, tarry, sticky, or have blood or mucus</item>
                                 <item>severe stomach-area (abdomen) pain or tenderness</item>
                              </list>
                              <content styleCode="bold">Liver problems</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>yellowing of your skin or the whites of your eyes</item>
                                 <item>severe nausea or vomiting</item>
                                 <item>pain on the right side of your stomach area (abdomen)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>dark urine (tea colored)</item>
                                 <item>bleeding or bruising more easily than normal</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Hormone gland problems</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>headaches that will not go away or unusual headaches</item>
                                 <item>eye sensitivity to light</item>
                                 <item>eye problems</item>
                                 <item>rapid heartbeat</item>
                                 <item>increased sweating</item>
                                 <item>extreme tiredness</item>
                                 <item>weight gain or weight loss</item>
                                 <item>feeling more hungry or thirsty than usual</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>urinating more often than usual</item>
                                 <item>hair loss</item>
                                 <item>feeling cold</item>
                                 <item>constipation</item>
                                 <item>your voice gets deeper</item>
                                 <item>dizziness or fainting</item>
                                 <item>changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Kidney problems</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>decrease in your amount of urine</item>
                                 <item>blood in your urine</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>swelling in your ankles</item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Skin problems</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>rash</item>
                                 <item>itching</item>
                                 <item>skin blistering or peeling</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>painful sores or ulcers in your mouth or in your nose, throat, or genital area</item>
                                 <item>fever or flu-like symptoms</item>
                                 <item>swollen lymph nodes</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with TEVIMBRA. Call or see your healthcare provider right away for new or worsening symptoms, which may include</content>:<list listType="unordered" styleCode="disc">
                                 <item>chest pain, irregular heartbeat, shortness of breath, swelling of ankles</item>
                                 <item>confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs</item>
                                 <item>double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight</item>
                                 <item>persistent or severe muscle pain or weakness, muscle cramps</item>
                                 <item>low red blood cells, bruising</item>
                              </list>
                              <content styleCode="bold">Infusion reactions that can sometimes be severe or life-threatening. Signs or symptoms of infusion reactions may include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>chills or shaking</item>
                                 <item>itching or rash</item>
                                 <item>flushing</item>
                                 <item>shortness of breath or wheezing</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>dizziness</item>
                                 <item>feeling like passing out</item>
                                 <item>fever</item>
                                 <item>back or neck pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Rejection of a transplanted organ or tissue.</content> Your healthcare provider should tell you what signs and symptoms you should report and monitor you, depending on the type of organ or tissue transplant that you have had.<br/>
                              <content styleCode="bold">Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).</content> These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with TEVIMBRA. Your healthcare provider will monitor you for these complications.<br/>
                              <content styleCode="bold">Getting medical treatment right away may help keep these problems from becoming more serious.</content>
                              <br/>Your healthcare provider will check you for these problems during your treatment with TEVIMBRA. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TEVIMBRA if you have severe side effects.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is TEVIMBRA?</content>
                              <br/>TEVIMBRA is a prescription medicine used to treat adults with:<list listType="unordered" styleCode="disc">
                                 <item>cancer of the tube that connects your throat to your stomach (esophageal cancer).<list listType="unordered" styleCode="circle">
                                       <item>TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer:<list listType="unordered" styleCode="square">
                                             <item>is a type called squamous cell carcinoma, <content styleCode="bold">and</content>
                                             </item>
                                             <item>cannot be removed with surgery or has spread to other parts of the body (metastatic), <content styleCode="bold">and</content>
                                             </item>
                                             <item>your tumor tests positive for "PD-L1."</item>
                                          </list>
                                       </item>
                                       <item>TEVIMBRA may be used alone when your esophageal cancer:<list listType="unordered" styleCode="square">
                                             <item>is a type called squamous cell carcinoma, <content styleCode="bold">and</content>
                                             </item>
                                             <item>cannot be removed with surgery or has spread to other parts of the body (metastatic), <content styleCode="bold">and</content>
                                             </item>
                                             <item>you have had previous treatment that did not include a PD-(L)1 inhibitor medicine.</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                                 <item>cancer of the stomach (gastric cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer).<list listType="unordered" styleCode="circle">
                                       <item>TEVIMBRA may be used in combination with chemotherapy that contains platinum and fluoropyrimidine as your first treatment when your gastric or gastroesophageal junction cancer:<list listType="unordered" styleCode="square">
                                             <item>cannot be removed with surgery or has spread to other parts of the body (metastatic), <content styleCode="bold">and</content>
                                             </item>
                                             <item>your tumor tests positive for "PD-L1."</item>
                                          </list>
                                       </item>
                                    </list>
                                 </item>
                              </list>It is not known if TEVIMBRA is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before receiving TEVIMBRA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have immune system problems such as Crohn's disease, ulcerative colitis, or lupus</item>
                                 <item>have received an organ or tissue transplant, including corneal transplant</item>
                                 <item>have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)</item>
                                 <item>have received radiation treatment to your chest area</item>
                                 <item>have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome</item>
                                 <item>are pregnant or plan to become pregnant. TEVIMBRA can harm your unborn baby.<br/>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>Your healthcare provider will do a pregnancy test before you start treatment with TEVIMBRA.</item>
                                       <item>You should use an effective method of birth control during your treatment and for 4 months after your last dose of TEVIMBRA. Talk to your healthcare provider about birth control methods that you can use during this time.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TEVIMBRA.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if TEVIMBRA passes into your breast milk. Do not breastfeed during treatment with TEVIMBRA and for 4 months after your last dose of TEVIMBRA.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How will I receive TEVIMBRA?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Your healthcare provider will give you TEVIMBRA into your vein through an intravenous (IV) line over 30 to 60 minutes. </item>
                                 <item>TEVIMBRA is usually given every 3 weeks.</item>
                                 <item>Your healthcare provider will decide how many treatments you need.</item>
                                 <item>Your healthcare provider will do blood tests to check you for certain side effects.</item>
                                 <item>If you miss any appointment, call your healthcare provider as soon as possible to reschedule your appointment.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of TEVIMBRA?</content>
                              <br/>
                              <content styleCode="bold">TEVIMBRA may cause serious side effects. See "<linkHtml href="#important">What is the most important information I should know about TEVIMBRA?</linkHtml>"</content>
                              <br/>
                              <content styleCode="bold">The most common side effects of TEVIMBRA when used in combination with platinum-containing chemotherapy include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>decreased white blood cell count</item>
                                 <item>decreased salt (sodium) in your blood</item>
                                 <item>increased glucose in your blood</item>
                                 <item>decreased red blood cell count (anemia)</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered">
                                 <item>tiredness</item>
                                 <item>decreased appetite</item>
                                 <item>increase in certain liver blood tests</item>
                                 <item>decreased potassium in your blood</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered">
                                 <item>increase in certain kidney blood tests</item>
                                 <item>decreased calcium in your blood</item>
                                 <item>diarrhea</item>
                                 <item>mouth sores</item>
                                 <item>vomiting</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of TEVIMBRA when used alone include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>increased blood sugar</item>
                                 <item>decreased red blood cell (anemia) and white blood cell counts </item>
                                 <item>decreased salt (sodium) in your blood</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered">
                                 <item>decreased albumin in the blood</item>
                                 <item>increase in certain liver blood tests </item>
                                 <item>tiredness</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered">
                                 <item>muscle and bone pain</item>
                                 <item>decreased weight</item>
                                 <item>cough</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered">
                                 <item>nausea</item>
                                 <item>tiredness</item>
                                 <item>decreased appetite</item>
                                 <item>decreased red blood cell count (anemia)</item>
                                 <item>numbness, pain, tingling, or burning in your hands or feet</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered">
                                 <item>vomiting</item>
                                 <item>decreased platelet count</item>
                                 <item>decreased white blood cell count</item>
                                 <item>increase in certain liver blood tests</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered">
                                 <item>diarrhea</item>
                                 <item>stomach-area (abdominal) pain</item>
                                 <item>decreased weight</item>
                                 <item>fever </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">These are not all the possible side effects of TEVIMBRA.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of TEVIMBRA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider or pharmacist for more information about TEVIMBRA that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in TEVIMBRA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> tislelizumab-jsgr<br/>
                              <content styleCode="bold">Inactive ingredients:</content> citric acid monohydrate, histidine, L-histidine hydrochloride monohydrate, polysorbate 20, sodium citrate, trehalose, and Water for Injection.<br/>
                              <content styleCode="bold">Manufactured by</content>: BeiGene USA, Inc. San Mateo, CA 94404<br/>U.S. License No. 2232<br/>TEVIMBRA<sup>®</sup> is a registered trademark owned by BeiGene, Ltd.<br/>© BeiGene, Ltd. 2025<br/>For more information, call 1-833-969-2463 or go to www.TEVIMBRA.com</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250306"/>
            </section>
         </component>
         <component>
            <section>
               <id root="192cf49b-e40b-4f1b-85cc-f198d3984ce7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</title>
               <text>
                  <paragraph>NDC 72579-121-01<br/>Rx only</paragraph>
                  <paragraph>TEVIMBRA<sup>®</sup>
                     <br/>tislelizumab-jsgr<br/>injection</paragraph>
                  <paragraph>100 mg/10 mL<br/>(10 mg/mL)</paragraph>
                  <paragraph>For Intravenous Infusion<br/>After Dilution</paragraph>
                  <paragraph>Dispense with Medication Guide</paragraph>
                  <paragraph>One 10 mL single-dose vial<br/>Discard unused portion</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20250306"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="tevimbra-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>